POLICY STATEMENT:

Based upon our criteria and review of the peer-reviewed literature, whole exome sequencing (WES) and whole genome sequencing (WGS) is considered investigational for the diagnosis of genetic disorders.

POLICY GUIDELINES:

I. The Health Plan and its employees adhere to all state and federal laws concerning the confidentiality of genetic testing and the results of genetic testing. All records, findings and results of any genetic test performed on any person shall be deemed confidential and shall not be disclosed without the written informed consent of the person to whom such genetic test relates. This information shall not be released to any person or organization not specifically authorized by the individual subject of the test.

II. Whole exome sequencing (WES) and whole genome sequencing (WGS) should only be offered in a setting with adequately trained health care providers (e.g., medical geneticist or an affiliated genetic counselor) to provide appropriate pre-and post-test genetic counseling that will guide decisions regarding treatment options.

III. Laboratories performing clinical tests must be certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA).

IV. If the genetic test is being done for knowledge only and that knowledge will not alter management or treatment of the patient or family member then the testing is not medically appropriate.

Refer to Corporate Medical Policy #2.02.03 Genetic Testing for Inherited Disorders

Refer to Corporate Medical Policy #2.02.42 Array Comparative Genomic Hybridization (aCGH) for the Genetic Evaluation of Patients with Developmental Delay, Mental Retardation or Autism Spectrum Disorder

Refer to Corporate Medical Policy #4.01.03 Preconception and Prenatal Genetic Testing/Counseling and Preimplantation Genetic Diagnosis (PGD)

DESCRIPTION:

Diagnostic confirmation of an individual with features suggestive of an inheritable disease (Mendelian disorder) may include traditional molecular and conventional diagnostic tests which may still yield an inconclusive clinical diagnosis after exhaustive and expensive testing. These individuals may be candidates for whole exome sequencing (WES) or whole genome sequencing (WGS). Whole exome sequencing or whole genome sequencing utilizes next-generation or massively parallel sequencing technology which allows multiple genes to be analyzed at one time and may return a pathogenic variant that is associated with a gene-causing disease. Whole genome sequencing processes genomic DNA (both coding and non-coding portions of the gene) followed by a series of computational analyses to determine the sequence of the sample DNA as compared to a reference DNA sequence. Whole genome sequencing is able to evaluate about 90% of the genome. Whole exome sequencing is targeted sequencing of the subset of the human genome that contains functionally important sequences of the protein-coding DNA and comprises approximately 1.5% of the genome and contains approximately 85% of highly penetrant genetic disease DNA variations. To perform whole exome sequence testing, the genomic DNA is hybridized to artificial DNA which is then sequenced similarly to whole genome sequencing. Approximately 85-90% of the exome is covered by whole exome sequencing with less effective coverage in the non-protein-coding portion of the genes. Standards for testing methods, reporting of results, interpretation of results as well as
social and ethical questions are areas where additional research is still needed before whole genome or exome sequencing can be incorporated into clinical practice.

Whole genome or whole exome sequencing results include three distinct categories: a variant known to cause human diseases, a variant suspected to cause human disease, and a variant of uncertain significance. Standards, or algorithms still need to be developed to insure accuracy, interpretation of results, continuing assessment of gene variants, as well as, ethical issues. Studies have shown technical difficulties in reproducing and confirming variations by another second testing method. Identification of genetic variants and their significance relies on the database that is used. Current databases are inconsistent with variable information and there is no set standard for updating these databases. There is no standardization in the approach of reporting incidental findings to individuals or the implications of reporting benign or catastrophic disease. More research is needed to expand databases, standardize test methods and interpretation of results and reporting of results for whole exome and whole genome sequencing to be incorporated into clinical practice instead of its use as a research tool.

RATIONALE:

Published exome sequencing studies show that the technology can be used to detect previously cataloged pathogenic mutations and reveal new likely pathogenic mutations in known and unknown genes. In addition, whole exome sequencing appears to have a higher diagnostic yield, quicker return of results, and is more efficient compared to traditional Sanger sequencing.

A 2013 Blue Cross Blue Shield Association TEC Special Report on exome sequencing for patients with suspected genetic disorders, stated there are currently no published studies that systematically examine potential outcomes of interest such as changes in medical management (including revision of initial diagnoses), and changes in reproductive decision making after a diagnosis of a Mendelian disorder by whole exome sequencing. A small number of studies of patient series, and a larger number of very small series or family studies report anecdotal examples of medical management and reproductive decision-making outcomes of exome sequencing in patients who were not diagnosed by traditional methods. These studies show that over and above traditional molecular and conventional diagnostic testing, exome sequencing can lead to a diagnosis that influences patient care and/or reproductive decisions, but gave no indication of the proportion of patients for which this is true. The publication of a large number of small diagnostic studies with positive results but few with negative results, raise the possibility of publication bias—the impact of which is unknown. Since publication of the 2013 TEC Special Report, studies continue to demonstrate that WES can be used to identify novel genetic mutations in a range of clinical conditions. However, evidence related to the use of WES test results in changes in medical management or reproductive decision making is limited.

The American College of Medical Genetics (ACMG) states that diagnostic testing with WES (and WGS) should be considered in the clinical diagnostic assessment of a phenotypically affected individual when:

I. The phenotype or family history data strongly implicate a genetic etiology, but the phenotype does not correspond with a specific disorder for which a genetic test targeting a specific gene is available on a clinical basis.

II. A patient presents with a defined genetic disorder that demonstrates a high degree of genetic heterogeneity, making WES or WGS analysis of multiple genes simultaneously a more practical approach.

III. A patient presents with a likely genetic disorder but specific genetic tests available for that phenotype have failed to arrive at a diagnosis.

IV. A fetus with a likely genetic disorder in which specific genetic tests, including targeted sequencing tests, available for that phenotype have failed to arrive at a diagnosis.

The ACMG states that for screening purposes WGS/WES may be considered in preconception carrier screening, using a strategy to focus on genetic variants known to be associated with significant phenotypes in homozygous or hemizygous progeny.

ACMG states that WGS/WES should not be used at this time as an approach to prenatal screening, or as a first-tier approach for newborn screening.
In March 2013, an ACMG board finalized approval of their recommends for reporting incidental findings in WGS and WES. A working group determined that reporting some incidental findings would likely have medical benefit for the patients and families of patients undergoing clinical sequencing and recommended that when a report is issued for clinically indicated exome and genome sequencing, a minimum list of conditions, genes and variants should be routinely evaluated and reported to the ordering clinician.

**CODES:**

<table>
<thead>
<tr>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eligibility for reimbursement is based upon the benefits set forth in the member’s subscriber contract.</td>
<td></td>
</tr>
</tbody>
</table>

**CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.**

Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.

**CPT:**

81415 (E/I) Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis

81416 (E/I) Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis, each comparator exome (eg, parents, siblings) (List separately in addition to code for primary procedure)

81417 (E/I) Exome (eg, unexplained constitutional or heritable disorder or syndrome); re-evaluation of previously obtained exome sequence (eg, updated knowledge or unrelated condition/syndrome)

81425 (E/I) Genome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis

81426 (E/I) Genome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis, each comparator genome (eg, parents, siblings) (List separately in addition to code for primary procedure)

81427 (E/I) Genome (eg, unexplained constitutional or heritable disorder or syndrome); re-evaluation of previously obtained genome sequence (eg, updated knowledge or unrelated condition/syndrome)

**HCPCS:**

No specific code(s)

**ICD9:**

Numerous Diagnoses

**ICD10:**

Numerous Diagnoses

**REFERENCES:**


**KEY WORDS:**
Exome, genome, WES, WGS

---

**CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS**

There is currently no National Coverage Determination (NCD) or Local Coverage Determination (LCD) for whole exome or whole genome sequencing for diagnosis of genetic disorders.